Theriva Biologics (NYSEAMERICAN:TOVX) Posts Quarterly Earnings Results

Posted by Linda Flegge on May 6th, 2026

Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, FiscalAI reports.

Theriva Biologics Stock Up 0.1%

Shares of Theriva Biologics stock opened at $0.38 on Wednesday. The stock’s 50-day moving average is $0.24 and its 200 day moving average is $0.24. Theriva Biologics has a one year low of $0.16 and a one year high of $1.45. The firm has a market cap of $12.82 million, a price-to-earnings ratio of -0.01 and a beta of 1.17. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.74 and a quick ratio of 1.74.

Wall Street Analyst Weigh In

Separately, Maxim Group upgraded shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $1.00.

Get Our Latest Research Report on TOVX

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP acquired a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned approximately 0.64% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is currently owned by hedge funds and other institutional investors.

Theriva Biologics Company Profile

(Get Free Report)

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.